OBJECTIVE: We sought to explore the mechanisms leading to cerebral amyloid angiopathy (CAA)-related cortical superficial siderosis (cSS) by examining its neuroimaging and genetic association with cerebral microbleeds (CMBs). METHODS: MRI scans of 84 subjects with probable or definite CAA participating in a longitudinal research study were graded for cSS presence and severity (focal, restricted to ≤ 3 sulci vs disseminated, ≥ 4 sulci), and CMB count. APOE ε variants were directly genotyped. We performed cross-sectional analysis comparing CMB counts and APOE ε2 and ε4 allele frequency between subjects with no, focal, or disseminated cSS. RESULTS: cSS was present in 48% (n = 40) of the population. APOE ε2 was overrepresented among participants with focal (odds ratio [OR] 7.0, 95% confidence interval [CI] 1.7-29.3, p = 0.008) and disseminated (OR 11.5, 95% CI 2.8-46.2, p = 0.001) cSS relative to individuals without cSS. CMB counts decreased with increasing severity of cSS (median: 41, 38, and 15 for no cSS, focal cSS, and disseminated cSS, respectively, p = 0.09). The highest CMB count tertile was associated with APOE ε4 (OR 3.0, 95% CI 1.4-6.6, p = 0.006) relative to the lowest tertile. CONCLUSIONS: Among individuals with advanced CAA, cSS tends to occur in individuals with relatively lower CMB counts and with a distinct pattern of APOE genotypes. These results suggest that CAA-related cSS and CMBs may arise from distinct vasculopathic mechanisms.
OBJECTIVE: We sought to explore the mechanisms leading to cerebral amyloid angiopathy (CAA)-related cortical superficial siderosis (cSS) by examining its neuroimaging and genetic association with cerebral microbleeds (CMBs). METHODS: MRI scans of 84 subjects with probable or definite CAA participating in a longitudinal research study were graded for cSS presence and severity (focal, restricted to ≤ 3 sulci vs disseminated, ≥ 4 sulci), and CMB count. APOE ε variants were directly genotyped. We performed cross-sectional analysis comparing CMB counts and APOE ε2 and ε4 allele frequency between subjects with no, focal, or disseminated cSS. RESULTS:cSS was present in 48% (n = 40) of the population. APOE ε2 was overrepresented among participants with focal (odds ratio [OR] 7.0, 95% confidence interval [CI] 1.7-29.3, p = 0.008) and disseminated (OR 11.5, 95% CI 2.8-46.2, p = 0.001) cSS relative to individuals without cSS. CMB counts decreased with increasing severity of cSS (median: 41, 38, and 15 for no cSS, focal cSS, and disseminated cSS, respectively, p = 0.09). The highest CMB count tertile was associated with APOE ε4 (OR 3.0, 95% CI 1.4-6.6, p = 0.006) relative to the lowest tertile. CONCLUSIONS: Among individuals with advanced CAA, cSS tends to occur in individuals with relatively lower CMB counts and with a distinct pattern of APOE genotypes. These results suggest that CAA-related cSS and CMBs may arise from distinct vasculopathic mechanisms.
Authors: J A Nicoll; C Burnett; S Love; D I Graham; D Dewar; J W Ironside; J Stewart; H V Vinters Journal: Ann Neurol Date: 1997-06 Impact factor: 10.422
Authors: S M Greenberg; J P Vonsattel; A Z Segal; R I Chiu; A E Clatworthy; A Liao; B T Hyman; G W Rebeck Journal: Neurology Date: 1998-04 Impact factor: 9.910
Authors: M O McCarron; J A Nicoll; J Stewart; J W Ironside; D M Mann; S Love; D I Graham; D Dewar Journal: J Neuropathol Exp Neurol Date: 1999-07 Impact factor: 3.685
Authors: Steven M Greenberg; R N Kaveer Nandigam; Pilar Delgado; Rebecca A Betensky; Jonathan Rosand; Anand Viswanathan; Matthew P Frosch; Eric E Smith Journal: Stroke Date: 2009-05-14 Impact factor: 7.914
Authors: Steven M Greenberg; Meike W Vernooij; Charlotte Cordonnier; Anand Viswanathan; Rustam Al-Shahi Salman; Steven Warach; Lenore J Launer; Mark A Van Buchem; Monique Mb Breteler Journal: Lancet Neurol Date: 2009-02 Impact factor: 44.182
Authors: Andreas Charidimou; Jun Ni; Sergi Martinez-Ramirez; Anastasia Vashkevich; Alison Ayres; Jonathan Rosand; Edip M Gurol; Steven M Greenberg; Anand Viswanathan Journal: Cerebrovasc Dis Date: 2016-01-12 Impact factor: 2.762
Authors: Hyemin Jang; Young Kyoung Jang; Hee Jin Kim; David John Werring; Jin San Lee; Yeong Sim Choe; Seongbeom Park; Juyeon Lee; Ko Woon Kim; Yeshin Kim; Soo Hyun Cho; Si Eun Kim; Seung Joo Kim; Andreas Charidimou; Duk L Na; Sang Won Seo Journal: Eur J Nucl Med Mol Imaging Date: 2019-04-02 Impact factor: 9.236
Authors: Andreas Charidimou; Gregoire Boulouis; M Edip Gurol; Cenk Ayata; Brian J Bacskai; Matthew P Frosch; Anand Viswanathan; Steven M Greenberg Journal: Brain Date: 2017-07-01 Impact factor: 13.501
Authors: Nina Lummel; Frank Arne Wollenweber; Philippe Demaerel; Katja Bochmann; Rainer Malik; Christian Opherk; Jennifer Linn Journal: J Neurol Date: 2015-04-11 Impact factor: 4.849
Authors: Ashkan Shoamanesh; Lesly A Pearce; Carlos Bazan; Luciana Catanese; Leslie A McClure; Mukul Sharma; Joan Marti-Fabregas; David C Anderson; Carlos S Kase; Robert G Hart; Oscar R Benavente Journal: Ann Neurol Date: 2017-07-19 Impact factor: 10.422
Authors: Andreas Charidimou; Gregoire Boulouis; Li Xiong; Michel J Jessel; Duangnapa Roongpiboonsopit; Alison Ayres; Kristin M Schwab; Jonathan Rosand; M Edip Gurol; Steven M Greenberg; Anand Viswanathan Journal: Neurology Date: 2017-03-29 Impact factor: 9.910
Authors: Thanakit Pongpitakmetha; Panagiotis Fotiadis; Marco Pasi; Gregoire Boulouis; Li Xiong; Andrew D Warren; Kristin M Schwab; Jonathan Rosand; M Edip Gurol; Steven M Greenberg; Anand Viswanathan; Andreas Charidimou Journal: Neurology Date: 2020-04-13 Impact factor: 9.910
Authors: Michael Pichler; Prashanthi Vemuri; Alejandro A Rabinstein; Jeremiah Aakre; Kelly D Flemming; Robert D Brown; Neeraj Kumar; Kejal Kantarci; Walter Kremers; Michelle M Mielke; David S Knopman; Clifford R Jack; Ronald C Petersen; Val Lowe; Jonathan Graff-Radford Journal: Stroke Date: 2017-10-25 Impact factor: 7.914
Authors: Y Inoue; M Nakajima; H Uetani; T Hirai; M Ueda; M Kitajima; D Utsunomiya; M Watanabe; M Hashimoto; M Ikeda; Y Yamashita; Y Ando Journal: AJNR Am J Neuroradiol Date: 2015-10-08 Impact factor: 3.825